Position in TRDA
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$245,463
+$16,095 QoQ
Shares Held
33,351
+83.5% QoQ
Ownership
0.086%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#62
of 128 holders
Holding Since
Mar 2024
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TRDA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026HARBOR CAPITAL ADVISORS, INC. holds $28,134,645 across 28 Biotechnology names. TRDA ranks #19 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | KYMR |
Kymera Therapeutics, Inc.
|
36,368 | $4,170,318 | |
| 2 | VCEL |
Vericel Corp
|
72,852 | $3,241,185 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
36,977 | $2,894,189 | |
| 4 | RARE |
Ultragenyx Pharmaceutical Inc.
|
72,316 | $2,414,631 | |
| 5 | CELC |
Celcuity Inc.
|
19,933 | $2,085,390 | |
| 6 | TARS |
Tarsus Pharmaceuticals, Inc.
|
29,612 | $1,863,779 | |
| 7 | AGIO |
Agios Pharmaceuticals, Inc.
|
46,550 | $1,727,470 | |
| 8 | SRPT |
Sarepta Therapeutics, Inc.
|
92,669 | $1,665,261 |
All Filings in TRDA
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $245,463 | 33,351 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $229,368 | 18,175 | Shares | Sole | 2026-04-28 | |
| 2025-06-30 | $102,661 | 15,277 | Shares | Sole | 2025-07-09 | |
| 2025-03-31 | $121,163 | 13,403 | Shares | Sole | 2025-04-14 | |
| 2024-03-31 | $206,074 | 14,543 | Shares | Sole | 2024-05-13 | |
| No filing history on record for this holder in this stock. | ||||||